Description
Alecinix (Alectinib) is a kinase inhibitor used to treat adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have stopped responding to Crizotinib or can’t take it. Alecinix (Alectinib) is used as a first-line treatment for adults with advanced non-small cell lung cancer that is positive for anaplastic lymphoma kinase (ALK) (NSCLC)
Dosing & Administration
- Alectinib should be taken by mouth twice a day at a dose of 600 mg. Give Alectinib until the disease worsens or the side effects are too much.
- For people with severe liver damage (Child-Pugh C), the recommended dose of Alectiib is 450 mg twice a day.
- It is best to take Alectinib with food. Don’t open the capsule or try to get the contents out. If you miss a dose of Alectinib or throw up after taking an amount, take the next dose at the time you were supposed to.
Side Effects
- Hepatotoxicity
- Interstitial Lung Disease (ILD)/Pneumonitis
- Renal Impairment • Bradycardia
- Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
- Embryo-Foetal Toxicity
Breastfeeding Warnings
Since this drug is bound to plasma proteins more than 99 percent of the time, there is probably not much of it in breast milk. However, its half-life is 33 hours so that it may build up in the baby. It’s not a good idea to use. They do not know what gets into human milk.
Excreted into animal milk: Data not available
Comment: We don’t know how it will affect the baby and how much milk it will make.
-It is not a good idea to breastfeed during therapy or for a week.
Storage
Keep away from light and in a cool, dry place. Keep out of children’s reach.
Reviews
There are no reviews yet.